Denali Therapeutics (DNLI) Equity Average: 2018-2025
Historic Equity Average for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to $976.6 million.
- Denali Therapeutics' Equity Average fell 27.81% to $976.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $976.6 million, marking a year-over-year decrease of 27.81%. This contributed to the annual value of $1.1 billion for FY2024, which is 9.03% up from last year.
- Latest data reveals that Denali Therapeutics reported Equity Average of $976.6 million as of Q3 2025, which was down 9.14% from $1.1 billion recorded in Q2 2025.
- In the past 5 years, Denali Therapeutics' Equity Average registered a high of $1.4 billion during Q2 2024, and its lowest value of $847.9 million during Q3 2022.
- Its 3-year average for Equity Average is $1.2 billion, with a median of $1.2 billion in 2023.
- In the last 5 years, Denali Therapeutics' Equity Average spiked by 139.94% in 2021 and then fell by 27.81% in 2025.
- Quarterly analysis of 5 years shows Denali Therapeutics' Equity Average stood at $987.3 million in 2021, then decreased by 6.12% to $926.9 million in 2022, then grew by 15.94% to $1.1 billion in 2023, then climbed by 18.56% to $1.3 billion in 2024, then dropped by 27.81% to $976.6 million in 2025.
- Its Equity Average was $976.6 million in Q3 2025, compared to $1.1 billion in Q2 2025 and $1.2 billion in Q1 2025.